Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moog, F.
Right arrow Articles by Reske, S. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moog, F.
Right arrow Articles by Reske, S. N.

Radiology, Vol 206, 475-481, Copyright © 1998 by Radiological Society of North America

ARTICLES

Extranodal malignant lymphoma: detection with FDG PET versus CT

F Moog, M Bangerter, CG Diederichs, A Guhlmann, E Merkle, N Frickhofen and SN Reske
Department of Nuclear Medicine, University of Ulm, Germany.

PURPOSE: To evaluate use of functional imaging with positron emission tomography (PET) versus computed tomography (CT) for detection of extranodal lymphoma spread. MATERIALS AND METHODS: Eighty-one consecutive and previously untreated patients with malignant non- Hodgkin lymphoma (n = 43) or Hodgkin disease (n = 38) were examined with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) PET and contrast material-enhanced CT. Concordant findings at both CT and FDG PET were regarded as actual locations of disease; discordant results were resolved on the basis of biopsy or follow-up results when possible. RESULTS: Forty-two lesions were identified at both PET and CT, and 19 were verified with biopsy results. PET demonstrated a further 24 lesions. Verification was possible in 15 of these lesions with biopsy (n = 10), magnetic resonance imaging (n = 1), scintigraphic (n = 1), or follow-up (n = 3) results. In 14 of these 15 lesions, PET findings were confirmed (bone marrow, nine; spleen, three; other, two). Seven lesions not visualized at FDG PET were identified at CT, six of which were verified with biopsy (n = 2) or follow-up (n = 4) results. Five of these six CT findings were found to be erroneous. In 13 patients, PET findings led to changes in tumor staging. CONCLUSION: PET may provide more information about extranodal lymphoma than does incremental CT.


This article has been cited by other articles:


Home page
 BloodHome page
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood, November 15, 2007; 110(10): 3507 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
N. A. Bakker and G. W. van Imhoff
Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention?
Haematologica, November 1, 2007; 92(11): 1447 - 1450.
[Full Text] [PDF]

Home page
 RadioGraphicsHome page
N. P. Leite, N. Kased, R. F. Hanna, M. A. Brown, J. M. Pereira, R. Cunha, and C. B. Sirlin
Cross-sectional Imaging of Extranodal Involvement in Abdominopelvic Lymphoproliferative Malignancies
RadioGraphics, November 1, 2007; 27(6): 1613 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
N. G. Schaefer, C. Taverna, K. Strobel, C. Wastl, M. Kurrer, and T. F. Hany
Hodgkin Disease: Diagnostic Value of FDG PET/CT after First-Line Therapy--Is Biopsy of FDG-avid Lesions Still Needed?
Radiology, July 1, 2007; 244(1): 257 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al.
Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
Clin. Cancer Res., June 15, 2007; 13(12): 3552 - 3558.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, et al.
Molecular Imaging of Proliferation in Malignant Lymphoma.
Cancer Res., November 15, 2006; 66(22): 11055 - 11061.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
S. Sheth, S. Ali, and E. Fishman
Imaging of renal lymphoma: patterns of disease with pathologic correlation.
RadioGraphics, July 1, 2006; 26(4): 1151 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
S. KAWAI, E. IKEDA, M. SUGIYAMA, J. MATSUMOTO, T. HIGUCHI, H. ZHANG, N. KHAN, K. TOMIYOSHI, T. INOUE, H. YAMAGUCHI, et al.
ENHANCEMENT OF SPLENIC GLUCOSE METABOLISM DURING ACUTE MALARIAL INFECTION: CORRELATION OF FINDINGS OF FDG-PET IMAGING WITH PATHOLOGICAL CHANGES IN A PRIMATE MODEL OF SEVERE HUMAN MALARIA.
Am J Trop Med Hyg, March 1, 2006; 74(3): 353 - 360.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. E. Juweid
Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma
Hematology, January 1, 2006; 2006(1): 259 - 265.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
M. Tatsumi, C. Cohade, Y. Nakamoto, E. K. Fishman, and R. L. Wahl
Direct Comparison of FDG PET and CT Findings in Patients with Lymphoma: Initial Experience
Radiology, December 1, 2005; 237(3): 1038 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Schoder, A. Noy, M. Gonen, L. Weng, D. Green, Y. E. Erdi, S. M. Larson, and H. W.D. Yeung
Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol., July 20, 2005; 23(21): 4643 - 4651.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. E. Pakos, A. D. Fotopoulos, and J. P.A. Ioannidis
18F-FDG PET for Evaluation of Bone Marrow Infiltration in Staging of Lymphoma: A Meta-Analysis
J. Nucl. Med., June 1, 2005; 46(6): 958 - 963.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
U. Metser, E. Miller, A. Kessler, H. Lerman, G. Lievshitz, R. Oren, and E. Even-Sapir
Solid Splenic Masses: Evaluation with 18F-FDG PET/CT
J. Nucl. Med., January 1, 2005; 46(1): 52 - 59.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac
FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls
RadioGraphics, January 1, 2005; 25(1): 191 - 207.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Kumar, Y. Xiu, S. Potenta, A. Mavi, H. Zhuang, J. Q. Yu, T. Dhurairaj, S. Dadparvar, and A. Alavi
18F-FDG PET for Evaluation of the Treatment Response in Patients with Gastrointestinal Tract Lymphomas
J. Nucl. Med., November 1, 2004; 45(11): 1796 - 1803.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
N. G. Schaefer, T. F. Hany, C. Taverna, B. Seifert, K. D. M. Stumpe, G. K. von Schulthess, and G. W. Goerres
Non-Hodgkin Lymphoma and Hodgkin Disease: Coregistered FDG PET and CT at Staging and Restaging--Do We Need Contrast-enhanced CT?
Radiology, September 1, 2004; 232(3): 823 - 829.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
U. Metser, O. Goor, H. Lerman, E. Naparstek, and E. Even-Sapir
PET-CT of Extranodal Lymphoma
Am. J. Roentgenol., June 1, 2004; 182(6): 1579 - 1586.
[Full Text] [PDF]

Home page
 The OncologistHome page
J. W. Friedberg and V. Chengazi
PET Scans in the Staging of Lymphoma: Current Status
Oncologist, October 1, 2003; 8(5): 438 - 447.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Wagner, U. Seitz, A. Buck, B. Neumaier, S. Schultheiss, M. Bangerter, M. Bommer, F. Leithauser, E. Wawra, G. Munzert, et al.
3'-[18F]Fluoro-3'-Deoxythymidine ([18F]-FLT) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease
Cancer Res., May 15, 2003; 63(10): 2681 - 2687.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
R. Bar-Shalom, N. Yefremov, N. Haim, E. J. Dann, R. Epelbaum, Z. Keidar, D. Gaitini, A. Frenkel, and O. Israel
Camera-based FDG PET and 67Ga SPECT in Evaluation of Lymphoma: Comparative Study
Radiology, May 1, 2003; 227(2): 353 - 360.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. V. Dizendorf, B. G. Baumert, G. K. von Schulthess, U. M. Lutolf, and H. C. Steinert
Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients for Radiation Therapy
J. Nucl. Med., January 1, 2003; 44(1): 24 - 29.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
O. Israel, M. Mekel, R. Bar-Shalom, R. Epelbaum, N. Hermony, N. Haim, E. J. Dann, A. Frenkel, M. Ben-Arush, and D. Gaitini
Bone Lymphoma: 67Ga Scintigraphy and CT for Prediction of Outcome After Treatment
J. Nucl. Med., October 1, 2002; 43(10): 1295 - 1303.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Kostakoglu, M. Coleman, J. P. Leonard, I. Kuji, H. Zoe, and S. J. Goldsmith
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin's Disease
J. Nucl. Med., August 1, 2002; 43(8): 1018 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 ImagingHome page
S F Barrington
Whole body applications of positron emission tomography in oncology
Imaging, September 1, 2001; 13(3): 185 - 196.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Schoder, J. Meta, C. Yap, M. Ariannejad, J. Rao, M. E. Phelps, P. E. Valk, J. Sayre, and J. Czernin
Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma
J. Nucl. Med., August 1, 2001; 42(8): 1139 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps
A Tabulated Summary of the FDG PET Literature
J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93.
[Full Text] [PDF]

Home page
 JNMHome page
M. Tatsumi, H. Kitayama, H. Sugahara, N. Tokita, H. Nakamura, Y. Kanakura, and T. Nishimura
Whole-Body Hybrid PET with 18F-FDG in the Staging of Non-Hodgkin's Lymphoma
J. Nucl. Med., April 1, 2001; 42(4): 601 - 608.
[Abstract] [Full Text]

Home page
 JNMHome page
G. M. Segall
FDG PET Imaging in Patients with Lymphoma: A Clinical Perspective
J. Nucl. Med., April 1, 2001; 42(4): 609 - 610.
[Full Text]

Home page
 JAMAHome page
C. M. C. Tempany and B. J. McNeil
Advances in Biomedical Imaging
JAMA, February 7, 2001; 285(5): 562 - 567.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. J. Lugtenburg, B. Löwenberg, R. Valkema, H.-Y. Oei, S. W. Lamberts, M. J. Eijkemans, W. L. van Putten, and E. P. Krenning
Somatostatin Receptor Scintigraphy in the Initial Staging of Low-Grade Non-Hodgkin's Lymphomas
J. Nucl. Med., February 1, 2001; 42(2): 222 - 229.
[Abstract] [Full Text]

Home page
 JCOHome page
K. Spaepen, S. Stroobants, P. Dupont, S. Van Steenweghen, J. Thomas, P. Vandenberghe, L. Vanuytsel, G. Bormans, J. Balzarini, C. De Wolf-Peeters, et al.
Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin's Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
J. Clin. Oncol., January 15, 2001; 19(2): 414 - 419.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. Sutinen, S. Jyrkkio, M. Varpula, P. Lindholm, T. Gronroos, P. Lehikoinen, M. Teras, and H. Minn
Nodal Staging of Lymphoma with Whole-Body PET: Comparison of [11C]Methionine and FDG
J. Nucl. Med., December 1, 2000; 41(12): 1980 - 1988.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1998 by the Radiological Society of North America.